ly3437943 retatrutide triple agonist glp-1 gip glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

Five liver samples (200 mg each) were spiked with either 50, 100, 200, 300, or 400 M GSH prior to extraction

Trimethylaminuria (TMAU, fish odor syndrome) is an uncommon condition that makes people smell like rotten fish

The FDA says that they would not take action against a compounder for using a Category 1 substance but would consider taking action for those that use Category 2 or 3 substances

How to Take Them (and Combine If Desired) L-theanine Usage: Take 100-200 mg once or twice daily, with or without food

CagriSema submitted for FDA approval in December 2025 with expected approval in Q4 2026 or Q1 2027, meaning launch around mid-2027

Safety remains a top priority